Edition:
India

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

3.41USD
22 Jun 2018
Change (% chg)

$-0.22 (-6.06%)
Prev Close
$3.63
Open
$3.62
Day's High
$3.69
Day's Low
$3.38
Volume
1,254,648
Avg. Vol
25,316
52-wk High
$10.67
52-wk Low
$3.10

Select another date:

Thu, May 10 2018

BRIEF-Novelion Therapeutics Reports Quarterly Net Loss Per Share Of $1.76

* NOVELION THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Novelion Therapeutics Reports Gaap Net Loss In Q4 Of 2017

* NOVELION THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Doctor admits disclosing patient info to drugmaker Aegerion

BOSTON A Georgia pediatric cardiologist pleaded guilty on Wednesday to wrongfully disclosing information about his young patients to an Aegerion Pharmaceuticals Inc sales representative seeking to identify potential new users of an expensive cholesterol drug.

BRIEF-Partner Therapeutics Acquires Leukine From Sanofi

* PARTNER THERAPEUTICS INC - HAS ACQUIRED GLOBAL RIGHTS TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE LEUKINE (SARGRAMOSTIM) FROM SANOFI

BRIEF-Novelion Says U.S. District Court Judge Sentenced Unit Aegerion Pharmaceuticals

* NOVELION THERAPEUTICS INC - ANNOUNCED THAT A U.S. DISTRICT COURT JUDGE HAS SENTENCED NOVELION SUBSIDIARY AEGERION PHARMACEUTICALS

U.S. judge sentences Novelion's Aegerion in drug marketing case

BOSTON A federal judge on Tuesday sentenced Aegerion Pharmaceuticals Inc for improperly marketing a cholesterol drug and ordered that some of the $40.1 million it agreed to pay to resolve a U.S. investigation go to the company's victims.

UPDATE 1-U.S. judge sentences Novelion's Aegerion in drug marketing case

BOSTON, Jan 30 A federal judge on Tuesday sentenced Aegerion Pharmaceuticals Inc for improperly marketing a cholesterol drug and ordered that some of the $40.1 million it agreed to pay to resolve a U.S. investigation go to the company's victims.

Novelion's Aegerion faces sentencing in U.S. drug marketing case

BOSTON, Jan 30 Aegerion Pharmaceuticals Inc is set to be sentenced on Tuesday for improperly marketing a cholesterol drug by a judge who rejected an initial plea deal and asked whether the drugmaker should be allowed to "collapse in disgrace."

BRIEF-Novelion Therapeutics Announces Cost Reduction Plans, Capital Structure Review

* NOVELION THERAPEUTICS ANNOUNCES COST REDUCTION PLANS AND CAPITAL STRUCTURE REVIEW

Select another date: